BioX

At Biox Medical, our mission is to make advanced preventative and predictive technologies readily available. We are the new standard in cancer prevention technology, offering reliable and innovative solutions for early detection. We are committed to redefining the way we distribute advanced medical technologies. We believe that everyone deserves access to the latest and most innovative solutions for cancer prevention and early detection. Biox Medical was founded with the goal of making advanced medical technologies more accessible to people around the UK. We began by partnering with one of the leading manufacturers in the industry to offer innovative solutions for Bowel cancer prevention and early detection to the UK public.

Bioomix was founded in 2021 based on research from SDU and UWA, that showed how 3D bioprinting, developed for biomedicine, could be repurposed successfully for environmental biology. Bioomix has its own research, testing, quality control, and production laboratories in Odense. Bioomix develops microbial solutions to problems in the agricultural, food, health and environmental sectors. Our vision is a circular and sustainable plant production system that benefits the farmer, the consumer, our society, the planet, and wildlife. We develop organic and sustainable microbial products for global challenges, and help end-users achieve economic and environmental sustainability. We believe that microorganisms hold the potential to solve many of our society’s greatest problems. It is a very ambitious goal, but our passion for change was the reason, we started Bioomix. We want to change our food sector to make it more productive and, at the same time, more sustainable.

From Analytical Development and Methods Qualification to Feasibility through Detail Design, bioX is a single-source solutions provider. The bioX Applications Lab provides a stage to conduct caparison, physical/mechanical, biological and chemical testing. Located in the Greater Boston Area, bioX delivers agile, focused, and relevant Process and Quality Engineering consulting on a global scale.

We develop wearable exoskeletons that support workers executing physically demanding tasks. Our products reduce workload, exhaustion and fatigue to ensure the workers' long-term wellbeing. After many years of exoskeleton research, Auxivo AG was founded in 2019 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. Stay informed with our latest and upcoming activities in product development and company events.

Here at Bioxis, we have created biomaterial scaffolds that help regenerate tissues, improve patient outcomes, and provide better healthcare opportunities for doctors. We are focused on developing medical devices based on patented biomaterials technology with potentially accelerated pathways to market. Through groundbreaking solutions, we develop popular products that help doctors improve the quality of care of their patients in the dermatology and medical aesthetic fields. Committed to providing innovative solutionsto the dermatological industry. Revolutionary, advanced, and very much in-demand; Bioxis specializes in the discovery, development, production, and commercialization of innovative regenerative medical products. Innovative Medical Device toTransform Aesthetic Medicine and Dermatology…. Building on Revolutionary ScienceTo Launch New Ideas & Popular Products.

At xBxBio, our vision is to redefine the landscape of healthcare by building a comprehensive, state-of-the-art software solution that seamlessly integrates biology, physics, chemistry, mathematics, artificial intelligence, machine learning, augmented reality, and virtual reality to accelerate drug discovery and research across the globe. Its xBxBio ™ platform will enable scientists to test far more variables faster than what is available today. We believe that we can improve the likelihood of success for compounds by 150% and that we can also reduce the cost of a typical 3 phase FDA clinical study by over $120 million, and shave 5 to 6 years off the process. Furthermore, we believe that development candidates with more optimized property profiles will have a higher probability of success in clinical development.